Article Text
Electronic pages
Correspondence
Towards standardisation of histopathological assessments of germinal centres and lymphoid structures in primary Sjögren's syndrome
Statistics from Altmetric.com
We read with great interest the study by Delli et al,1 indicating the potential value of baseline salivary gland histopathology to predict response to rituximab (RTX) therapy. In their study, the authors report that RTX treatment significantly affects local inflammation at different levels, including a decrease in numbers of lymphoepithelial lesions, area of focal infiltrates, numbers of B cells and germinal centres (GCs). Interestingly, the presence of a high number of CD20-expressing B cells in parotid gland biopsy at baseline predicted response to RTX treatment. We agree that these observations may facilitate personalised medicine in patients with primary Sjögren's syndrome (pSS). Importantly, the results from …